News

Public · Published

PGEN Stock Craters 27% After-Hours After Rival Inovio's Rare Disease Drug Receives FDA Approval

The FDA approved Inovio Pharmaceuticals' Voceryq for adults with recurrent respiratory papillomatosis, a rare disease also treated by Precigen's already-marketed PAPZIMEOS. The decision was supported by an open-label trial of 32 adults, and the FDA said post-approval studies are needed to confirm clinical benefit.

Published:

Updated:

What happened

The FDA approved Inovio Pharmaceuticals’ Voceryq for adults with recurrent respiratory papillomatosis, a rare disease also treated by Precigen’s already-marketed PAPZIMEOS. The decision was supported by an open-label trial of 32 adults, and the FDA said post-approval studies are needed to confirm clinical benefit.

Confirmed

Global impact / market context

A newly approved rival gives patients and clinicians another treatment option for the same rare disease, potentially dividing demand for PAPZIMEOS. If that reduces sales, Precigen could face weaker revenue from its marketed product; the supplied article does not say whether this has happened.

Analyst inference

The article reports a sharp after-hours decline in Precigen shares and a gain of more than 300% in Inovio shares after the FDA decision. It also says Voceryq’s approval is accelerated, meaning further studies are required to confirm clinical benefit.

Confirmed

What to watch

  1. Watch for Precigen disclosures on PAPZIMEOS prescriptions, sales, or revenue, which could show whether the newly approved competitor is drawing demand away from its treatment. Analyst inference
  2. Watch for Inovio’s required post-approval studies, which the FDA says must confirm clinical benefit; their results could affect confidence in Voceryq’s longer-term use. Confirmed
  3. Watch for any reported changes in treatment choices for recurrent respiratory papillomatosis, since greater use of Voceryq could reduce demand for repeated surgeries or competing treatment. Analyst inference

Evidence